SynthesisThe pharmacogenomics journal2026
Barriers and facilitators to the implementation of pharmacogenomic testing for antidepressants use in primary care: a systematic review using the consolidated framework for implementation research.
Synthesis in The pharmacogenomics journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomic (PGx) testing may improve antidepressant prescribing, but uptake in primary care is limited. The Consolidated Framework for Implementation Research (CFIR) can help identify determinants of implementation. To synthesise barriers and facilitators to implementing PGx-guided antidepressant prescribing in primary care using CFIR, we searched MEDLINE, EMBASE, Scopus, CINAHL, APA PsycINFO, and Web of Science to March 2025. Qualitative and mixed-methods studies were screened by two independent reviewers and analysed using a CFIR-informed framework. Thirteen studies (n = 979 records screened) involving clinicians, administrators, policymakers, and patients were included. Barriers included limited perceived evidence, cost and reimbursement uncertainty, intervention complexity, workflow disruption, and low clinician confidence. Facilitators included perceived relative advantage, pharmacist-led support, interprofessional collaboration, reimbursement, clinical integration, adaptable delivery models, and training. Our findings suggest that PGx testing is viewed as promising in primary care, but implementation is constrained by interrelated issues of clinical utility, cost, workflow integration, and immature implementation processes.
Indexed as
Identifiers
42716951What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.